Browsing Over 57 Sessions

Sort By

Daiichi Sankyo - Advances in Antibody Drug Conjugates in Solid Tumors: Current Treatments and Emerging Therapies  (ID 118)

Time
18:45 - 20:15

Deciphera Pharmaceuticals - Changing the paradigm in the management of advanced GIST: Current treatment landscape and new horizon (ID 153)

Time
10:30 - 12:00

Merck - Current and future treatments for head and neck cancer (ID 109)

Time
18:45 - 20:15

Bristol Myers Squibb - I-O Revolution: New Perspectives in the Treatment of Thoracic Cancers (ID 143)

Time
18:45 - 20:15

Servier - The clinical value of mIDH1 inhibition in cholangiocarcinoma (ID 100)

Time
08:45 - 10:15

Incyte - Making Precision Medicine a Reality for Patients with Cholangiocarcinoma (ID 133)

Time
18:45 - 19:58

AbbVie, Inc. - A Novel Approach to Targeting c-Met in Lung Cancer (ID 124)

Time
08:45 - 10:15

Pfizer Oncology - Confidence and clarity in advanced breast cancer: Insights from the real world  (ID 114)

Time
10:30 - 12:00

Boston Scientific - Expanding the treatment options for colorectal liver metastases with Y-90 radioembolisation: results of EPOCH study (ID 149)

Time
08:45 - 10:15

Novartis - Unmet needs in oncogene-driven NSCLC: how do we close the gap? (ID 105)

Time
10:30 - 12:00

Novartis - Staying on Track: Translating Evidence to Practice in Melanoma (ID 139)

Time
10:30 - 12:00

AstraZeneca - Osimertinib in early- and late-stage NSCLC: Breaking new ground in EGFRm disease (ID 129)

Time
10:30 - 12:00